Tag:
Epizyme
Latest Headlines
Latest Headlines
Kleiner Perkins to back early-stage biotechs with $525M fund
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
Epizyme builds epigenetics lineup with $90M Celgene score
The pact includes a commitment to pay tens of millions more in milestones for any successful therapies that come out of the deal.
Constellation inks $95M discovery deal, buyout option with Genentech
Epigenetics is a new field in drug discovery. But one of the pioneers of the science has already struck a lucrative partnership pact with Roche's Genentech that could pave the way to a buyout.
Epizyme scores $4M in ongoing GSK alliance
Epizyme took in a $4 million in milestone payments from partner GlaxoSmithKline ($GSK) after achieving some pre-clinical goals in the epigenetic alliance announced in January 2010. With up to $630
Constellation Pharma takes different route than rival in hot epigenetics field
With plenty of science to explore but limited funds, a biotech startup often faces the challenge of where to focus its time and money. At Constellation Pharmaceuticals , CEO Mark Goldsmith tells
Epizyme making big plans for pioneering epigenetics platform
Xconomy's Luke Timmerman spent some time with the CEO and CBO at Epizyme to see how the three-year-old biotech was able to score two impressive development deals with Big Pharma earlier this year.
Epizyme snags $206M epigenetics deal with Eisai
Just weeks after GlaxoSmithKline committed up to $650 million in its epigenetics pact with Cambridge, MA-based Epizyme , Japan's Eisai has hopped on board the promising discovery platform with a $206
Epizyme lands $650M GSK deal
GlaxoSmithKline is paying $20 million up front and more than $630 million in milestone payments for a partnership deal with Cambridge, MA based Epizyme. The biotech, which was founded in 2007, is
Epizyme amps up Series B to $40M
Epizyme has lured New Enterprise Associates into its venture capital fold and added former MedImmune CEO David Mott to the board. NEA added $8 million to the second round, bringing the total to $40
Epizyme pulls in $32M in VC capital, new investors
Cambridge, MA-based Epizyme garnered $32 million in a Series B financing round. New investors Bay City Capital, Amgen Ventures, and Astellas Venture Management were joined by existing investors MPM
